Home Bratislava Medical Journal 2020 Bratislava Medical Journal Vol.121, No.1, p.31–36,2020

Journal info


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564


Aims and Scope
Editorial Info
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.121, No.1, p.31–36,2020

Title: ZEB1 and ZEB2 gene editing mediated by CRISPR/Cas9 in A549 cell line
Author: R. Mohammadinejad, H. Sassan, A. Pardakhty, M. Hashemabadi, M. Ashrafizadeh, A. Dehshahri, A. Mandegary

Abstract: OBJECTIVES: One of the best approaches for recognition of protein function is the induction of mutations for a gene knockout. In line with this strategy, gene editing tools allow researchers to induce these mutations. Lung cancer is one of the leading causes of death worldwide. ZEB1 and ZEB2 genes are the candidates for this disease.
METHODS: The ZEB1 and ZEB2 knockout in the non-small cell lung cancer cell line (A549 cell) was investigated. Purification of recombination plasmids was performed from bacteria and then was transported to the A549 cell line. The deletion of ZEB1 and ZEB2 were examined by PCR.
RESULTS: The results demonstrated the mutation and deletion in ZEB1 and ZEB2 genes. Based on the findings of this study, A549 cells were transfected with the vectors carrying the sgRNA/Cas9, simultaneously. The DNA fragment demonstrated the presence of indels in target sites as well as provided the potential of CRISPR/Cas9 system.
CONCLUSION: CRISPR/Cas9 offers a great potential as an efficient technique for editing of ZEB1 and ZEB2 genes in A549 cell line (Tab. 1, Fig. 6, Ref. 44).

Keywords: CRISPR/Cas9, gene editing, ZEB1, ZEB2, lung cancer, A549
Published online: 17-Jan-2020
Year: 2020, Volume: 121, Issue: 1 Page From: 31, Page To: 36

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.